This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
by Zacks Equity Research
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Exelixis (EXEL) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Down 3.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
by Zacks Equity Research
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
by Zacks Equity Research
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Terns Surges 29.6% in Three Months: Will the Momentum Continue?
by Zacks Equity Research
TERN has outperformed the industry in the past three months on encouraging pipeline progress of its candidates. Positive data on obesity candidates should boost the stock further.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
by Zacks Equity Research
BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
Bayer Initiates Late-Stage Study on Investigational NSCLC Drug
by Zacks Equity Research
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
Zacks.com featured highlights Genpact, MPLX, Exelixis, Paramount Global and H&R Block
by Zacks Equity Research
Genpact, MPLX, Exelixis, Paramount Global and H&R Block have been highlighted in this Screen of The Week article.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
by Zacks Equity Research
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bayer, NextRNA to Develop Therapeutics Targeting Oncology
by Zacks Equity Research
BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
by Urmimala Biswas
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
by Zacks Equity Research
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
Why Exelixis (EXEL) Might be Well Poised for a Surge
by Zacks Equity Research
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bayer (BAYRY) Starts Mid-Stage Study on Chronic Kidney Disease Drug
by Zacks Equity Research
Bayer (BAYRY) advances its pipeline candidate BAY3283142 into phase II for the treatment of chronic kidney disease.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.